Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:38:15.489Z.
Calculation as of: 2026-10-06T19:38:15.489Z.
Quote observation: 2026-10-06T19:34:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 108f8fd7c16ea3ee173cf4c928fb1762d5fda8f0ed14c05de6879cdcb1b92349
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Sonoma Pharmaceuticals, Inc.
Market Cap
$5.79M
EV/EBIT Ratio
N/A
Market Cap
$5.63M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | $5.79M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.78M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.73M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.90M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.63M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.61M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $6.04M | N/A |
| Femasys Inc. (FEMY)vs › | $6.31M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.33M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
